SCHEMBL5451385

SCHEMBL5451385

CCOC(=O)c1c(NC(=O)c2ccc(F)c(F)c2)sc2c1CCOC2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 4/20 0.57
▸ MAPT P10636 4/20 0.56
▸ TP53 P04637 2/20 0.56
▸ THRB P10828 1/20 0.55
▸ ALDH1A1 P00352 6/20 0.55
▸ KDM4E B2RXH2 5/20 0.55
▸ HPGD P15428 4/20 0.55
▸ NPSR1 Q6W5P4 2/20 0.55
▸ LMNA P02545 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ USP2 O75604 3/20 0.51
▸ GAA P10253 2/20 0.51
▸ TSHR P16473 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ RAD52 P43351 1/20 0.51
▸ CFTR P13569 1/20 0.50
▸ HSD17B10 Q99714 3/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ CASP1 P29466 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19475093 0.86 ALDH1A1 (0.52) CNR2MAPTTP53THRBALDH1A1
SCHEMBL5467114 0.84 CFTR (0.64) CNR2CFTRMEN1KMT2A
SCHEMBL5460524 0.80 ALDH1A1 (0.56) CNR2MAPTALDH1A1KDM4ENPSR1
SCHEMBL5456095 0.80 ALDH1A1 (0.77) MAPTTP53ALDH1A1KDM4EHPGD
SCHEMBL5467525 0.79 ALDH1A1 (0.53) MAPTTP53ALDH1A1KDM4EHPGD
SCHEMBL5458226 0.79 ALDH1A1 (0.52) MAPTTP53ALDH1A1KDM4EHPGD
SCHEMBL34468609 0.77 MAPT (0.70) MAPTTP53THRBALDH1A1KDM4E
SCHEMBL5450569 0.77 KMT2A (0.69) CNR2MAPTALDH1A1KDM4EHPGD
SCHEMBL5458496 0.77 ALDH1A1 (0.56) CNR2MAPTALDH1A1KDM4EHPGD
SCHEMBL5453319 0.77 MAPT (0.53) CNR2MAPTALDH1A1KDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 — — US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 — — EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CNR2 2272/4885MAPT 21/4885TP53 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback